09/03/2026
Stanford University’s BRIDGE Lab is recruiting children with NF1, ages 2–8, who are about to begin treatment with the MEK inhibitor selumetinib, for the NF114 Brain and Behavior Study.
This research study aims to better understand brain development and behavior in young children with NF1, including how the brain and behavior may change over time as children begin MEK inhibitor treatment. The BRIDGE Lab is dedicated to improving our understanding of neurodevelopment in children with genetic conditions and identifying opportunities to support children’s mental health and development.
Participation includes a brief virtual visit and an in-person visit to our lab at Stanford University in Palo Alto, California. During the in-person visit, your child will complete age-appropriate assessments and an MRI scan. The full study takes approximately 1.5 days.
Travel and accommodation costs for eligible families will be covered. Participating families will also receive a $100 honorarium and a full neuropsychological research report.
Learn more: http://redcap.link/bridge_studies